Off-target risks remain a challenge in preclinical safety assessment. Traditional opinion-based secondary pharmacology profiling is often inconsistent and subjective. In this webinar, we introduce Certara’s Secondary Intelligence™ software to predict and analyze off-target risks enabling evidence-based secondary pharmacology insights.

In this webinar, you’ll learn:

• How to move from subjective to quantitative off-target safety assessment.
• How to benchmark your compound against real-world data. Discover how reference datasets from >100 known drug–target pairs provide objective context for interpreting safety risk.
• How to apply an evidence-based, automated workflow using Secondary Intelligence, illustrated through real compound case examples.

Adopt a data-driven, reproducible framework to gain confidence in your compound portfolio decisions, reduce subjective bias in safety risk interpretation, and streamline secondary pharmacology workflows. View the webinar to get started.